Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET BRAIN: Erenumab effects on brain networks in episodic migraine
NCT03977649Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of erenumab in migraine (2 arms), sponsored by Novartis. Primary endpoint: z-score maps change difference between-treatment-groups at 6 months. Started Jul 2019; status: completed.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03977649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03977649.